(Q40378149)

20 September 2017

title

Recent progress on sanofi pasteur's dengue vaccine candidate (English)

1 reference

20 September 2017

0 references

Jean Lang

1

1 reference

20 September 2017

publication date

1 October 2009

1 reference

Journal of Clinical Virology

20 September 2017

published in

1 reference

20 September 2017

volume

46 Suppl 2

1 reference

20 September 2017

page(s)

S20-4

1 reference

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781].

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2809%2970291-4

7 January 2021

10.1016/S1386-6532(09)70291-4

Identifiers

DOI

1 reference

release_czkl5cmlwzexlpjr47bppxwm7e

20 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/czkl5cmlwzexlpjr47bppxwm7e

24 November 2022

mapped directly with Wikidata item

1 reference